Stay updated on Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page.

Latest updates to the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedAdded revision v3.4.3 to the record history, replacing v3.4.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-lapse notice and Revision: v3.4.1.SummaryDifference0.9%

- Check41 days agoChange DetectedAdded a site-wide notice about a lapse in government funding affecting updates. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.9%

- Check48 days agoChange DetectedThe history page now features a Show glossary option and green/red color-coded highlights to indicate additions and deletions. It also displays the Revision: v3.4.0 release note while substantive study data remain unchanged; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check62 days agoChange DetectedActive, not recruiting as of 2026-01-07 is now shown, with new sections for Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Study Description, Study Status, and Study Identification. The previous version listed Not yet recruiting and the last known status was Liu Yunjiang, Hebei Medical University Fourth Hospital.SummaryDifference2%

- Check83 days agoChange DetectedRevision: v3.3.3 was added and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the page footer.SummaryDifference0.2%

Stay in the know with updates to Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page.